![]() |
![]() |
Teisinis statusas
Patentas neįsigaliojo (pagal EPK)
(51) | INT.CL. | A61K 39/395 | (2006.01) |
A61P 35/00 | (2018.01) | ||
A61P 35/00 | (2006.01) | ||
A61K 39/39558 | (2013.01) | ||
A61K 31/475 | (2006.01) | ||
C07K 16/2878 | (2013.01) | ||
A61K 31/573 | (2006.01) | ||
A61K2039/505 | (2013.01) | ||
A61K 31/655 | (2006.01) | ||
A61K2039/545 | (2013.01) | ||
A61K2039/55 | (2013.01) | ||
A61K 31/675 | (2006.01) | ||
A61K 31/704 | (2006.01) | ||
C07K2317/24 | (2013.01) | ||
A61K 45/06 | (2006.01) | ||
C07K2317/90 | (2013.01) | ||
C07K2317/94 | (2013.01) | ||
A61K 47/68 | (2017.01) | ||
A61P 35/02 | (2018.01) | ||
A61K 45/06 | (2013.01) | ||
A61K 31/475 | (2013.01) | ||
A61K 31/573 | (2013.01) | ||
A61K 31/655 | (2013.01) | ||
A61K 31/675 | (2013.01) | ||
A61K 31/704 | (2013.01) | ||
A61K 47/6849 | (2017.08) | ||
A61K 47/6867 | (2017.08) | ||
A61K 47/68031 | (2023.08) |
(11) | Patento numeris | 3538221 |
(13) | Dokumento rūšis | T |
(96) | Europos patento paraiškos numeris | 17808270.7 |
Europos patento paraiškos padavimo data | 2017-11-13 | |
(97) | Europos patento paraiškos paskelbimo data | 2019-09-18 |
(45) | Paskelbimo apie Europos patento išdavimą data | 2024-10-09 |
(46) | Apibrėžties vertimo paskelbimo data |
(86) | Numeris | PCT/US2017/061294 |
Data | 2017-11-13 |
(87) | Numeris | WO 2018/089890 |
Data | 2018-05-17 |
(30) | Numeris | Data | Šalis |
201662421527 P | 2016-11-14 | US |
(72) |
FASANMADE, Adedigbo , US
|
(73) |
Takeda Pharmaceutical Company Limited ,
1-1, Doshomachi 4-chome,
Chuo-ku,, Osaka-shi, Osaka,
JP
|
(54) | PEDIATRIC HUMAN DOSING OF THE ANTI-CD30 ANTIBODY-DRUG CONJUGATE BRENTUXIMAB VEDOTIN |
PEDIATRIC HUMAN DOSING OF THE ANTI-CD30 ANTIBODY-DRUG CONJUGATE BRENTUXIMAB VEDOTIN |